Dendreon 1Q Earnings a Mixed Bag

Dendreon (NASDAQOTH: DNDNQ  ) reported fiscal 2014 first-quarter earnings results before the market opened today. The biotech company's results beat analyst estimates on the bottom line, but came up short on revenue.

For the period ended March 31, Dendreon posted a net loss of $0.24 per share, up from a loss of $0.48 per share during the same period a year ago. The Street had been looking for a loss of $0.28 per share in the quarter.

Dendreon generated revenue of $68.8 million, which was up slightly from $67.6 million in the first quarter of fiscal 2013. Nevertheless, this was below analysts' estimate for first quarter revenue of $69.1 million. "This was the first quarter since the introduction of competition where we saw revenues grow as compared to the prior year, which confirms the progress we are making on a year-over-year basis," Dendreon CEO John Johnson said in a press release.

Dendreon has been aggressively cutting costs in an effort to improve profitability and become cash flow breakeven as quickly as possible. Costs of goods sold in the quarter were $37 million, or 53% of revenue, which is an improvement over the year-ago period in which costs accounted for 64% of total revenue. Meanwhile, sales of the company's Provenge cancer drug stabilized in the quarter, despite increased competition.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2949092, ~/Articles/ArticleHandler.aspx, 9/3/2015 11:13:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Tamara Rutter

I've been an analytical writer for The Motley Fool since 2011. I cover the sectors of Consumer Goods, Technology, and Industrials. Connect with me on Twitter using the handle, @TamaraRutter -- I'd love to hear from you!

Today's Market

updated Moments ago Sponsored by:
DOW 16,531.97 180.59 1.10%
S&P 500 1,971.64 22.78 1.17%
NASD 4,791.62 41.64 0.88%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.03 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: **